首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1547928

全球 DNA 修復藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global DNA Repair Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 DNA 修復藥物市場需求預計將從 2023 年的 70.2 億美元達到近 247.9 億美元的市場規模，2024-2032 年研究期間複合年成長率為 15.05%。

DNA 損傷導致遺傳物質結構改變。它會導致 DNA 結構中包含缺陷和異常，從而導致 DNA 突變。突變發生在編碼必需蛋白質或酵素的基因。因此，DNA 損傷阻礙了 DNA 的正常功能和性能，導致遺傳性疾病的發生。然而，人體有能力修復受損的 DNA 序列。 DNA 修復是一系列過程的組合，包括識別發生突變的細胞以及糾正編碼基因組中涉及的 DNA 分子。某些藥物如聚 ADP 核糖聚合酶 (PARP) 抑制劑可用於增強人體的 DNA 修復機制。 DNA修復藥物支持與DNA損傷和遺傳異常相關的治療。

市場動態

全球癌症盛行率正在迅速上升。基因突變會導致細胞生長失控，進而導致癌症。癌症是導致全球大量死亡的主要疾病之一。癌症盛行率的不斷上升正在推動全球 DNA 修復藥物市場的發展。此外，擴大採用先進的下一代技術來治療癌症和其他遺傳疾病，這也刺激了需求。重點廠商正在大規模投入研發，尋找有效的藥物解決方案來支持DNA修復機制。主要市場參與者採取的策略正在推動全球市場。 COVID-19 大流行正在支持藥物開發的研發，這可能會增強全球 DNA 修復藥物市場。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球 DNA 修復藥物市場的各個細分市場進行了包容性評估。 DNA 修復藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

DNA 修復藥物市場報告的這一部分提供了國家和地區層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

依藥物類型

塔拉佐帕尼
奧拉帕尼
尼拉帕尼
盧卡帕尼
其他藥物類型

按申請

乳癌
卵巢癌
腹膜癌
輸卵管癌
其他應用

按配銷通路

醫院藥房
零售藥局
其他分銷管道

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲 DNA 修復藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 DNA修復藥物市場的主要參與者包括阿斯特捷利康公司、Onxeo、強生公司、FoRx Therapeutics、艾伯維、Artios Pharma Limited、輝瑞公司、Breakpoint Therapeutics、Luciole Pharmaceuticals、默克公司、ClovisOncology Inc.、葛蘭素史克公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：DNA 修復藥物公司的競爭格局

DNA修復藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
AstraZeneca Plc

公司概況
公司收入
產品
最新動態

Onxeo

公司概況
公司收入
產品
最新動態

Johnson & Johnson

公司概況
公司收入
產品
最新動態

FoRx Therapeutics

公司概況
公司收入
產品
最新動態

AbbVie

公司概況
公司收入
產品
最新動態

Artios Pharma Limited

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Breakpoint Therapeutics

公司概況
公司收入
產品
最新動態

Luciole Pharmaceuticals

公司概況
公司收入
產品
最新動態

Merck KGaA

公司概況
公司收入
產品
最新動態

ClovisOncology Inc.

公司概況
公司收入
產品
最新動態

GlaxoSmithKline Plc

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11212424

The global demand for DNA Repair Drugs Market is presumed to reach the market size of nearly USD 24.79 Billion by 2032 from USD 7.02 Billion in 2023 with a CAGR of 15.05% under the study period 2024-2032.

DNA damage causes alteration of structure in genetic material. It causes the inclusion of deficiencies and abnormalities in the DNA structure, which leads to mutations in the DNA. The mutations take place in the genes coding for essential proteins or enzymes. Thus DNA damage hampers the proper functioning and performance of the DNA resulting in the development of genetic disorders. However, the human body is capable of repairing damaged DNA sequences. DNA repairing is a combination of processes altogether that includes identification of cells where the mutation has occurred and the correction of DNA molecules that are involved in the encoding genome. Certain drugs such as poly ADP ribose polymerase (PARP) inhibitors are used to enhance the body's DNA repairing mechanism. DNA repair drugs support the treatments related to DNA damage and genetic abnormalities.

MARKET DYNAMICS

The prevalence of cancer is rising rapidly across the globe. Mutations in the genes cause uncontrolled cell growth leading to cancer. Cancer is one of the major diseases responsible for a large number of deaths across the globe. The increasing prevalence of cancer is propelling the global DNA repair drugs market. Furthermore, the growing adoption of advanced next-generation technologies to treat cancer and other genetic diseases is fueling demand. The key manufacturers are investing in R & D on a large scale to find effective drug solutions to support the DNA repair mechanism. The strategies acquired by key market players are propelling the global market. COVID-19 pandemic is supporting the R & D in drug development that is likely to enhance the global DNA repair drugs market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of DNA Repair Drugs. The growth and trends of DNA Repair Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the DNA Repair Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Talazoparib
Olaparib
Niraparib
Rucaparib
Other Drug Types

By Application

Breast Cancer
Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Other Applications

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the DNA Repair Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the DNA Repair Drugs market include AstraZeneca Plc, Onxeo, Johnson & Johnson, FoRx Therapeutics, AbbVie, Artios Pharma Limited, Pfizer Inc., Breakpoint Therapeutics, Luciole Pharmaceuticals, Merck KGaA, ClovisOncology Inc., GlaxoSmithKline Plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. DNA REPAIR DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data
5.3. Analysis By Drug Type
5.4. Talazoparib Historic and Forecast Sales By Regions
5.5. Olaparib Historic and Forecast Sales By Regions
5.6. Niraparib Historic and Forecast Sales By Regions
5.7. Rucaparib Historic and Forecast Sales By Regions
5.8. Other Drug Types Historic and Forecast Sales By Regions

6. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data
6.3. Analysis By Application
6.4. Breast Cancer Historic and Forecast Sales By Regions
6.5. Ovarian Cancer Historic and Forecast Sales By Regions
6.6. Peritoneal Cancer Historic and Forecast Sales By Regions
6.7. Fallopian Tube Cancer Historic and Forecast Sales By Regions
6.8. Other Applications Historic and Forecast Sales By Regions

7. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
7.5. Retail Pharmacies Historic and Forecast Sales By Regions
7.6. Other Distribution Channels Historic and Forecast Sales By Regions

8. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE DNA REPAIR DRUGS COMPANIES

9.1. DNA Repair Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF DNA REPAIR DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. AstraZeneca Plc
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Onxeo
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Johnson & Johnson
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. FoRx Therapeutics
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. AbbVie
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Artios Pharma Limited
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Pfizer Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Breakpoint Therapeutics
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Luciole Pharmaceuticals
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Merck KGaA
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. ClovisOncology Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. GlaxoSmithKline Plc
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments